Burg Simpson is not currently pursuing new Topamax® cases.
The Food and Drug Administration (FDA) has issued a warning that Topamax® (generic: topiramate) could cause fetal harm in unborn babies. Topamax® is an anti-epileptic drug which is used to treat epilepsy in children and young adults.
According to its manufacturer, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Topamax® can also used to treat certain other types of psychiatric disorders and is the #1 prescribed brand for migraine prevention in the U.S.
New research conducted by the North American Antiepileptic Drug (AED) Pregnancy Registry recently indicated an increased risk of oral cleft defects in infants exposed to topiramate during the first trimester of pregnancy.
The publication of this research has led the FDA to issue a warning to pregnant mothers that exposure to Topamax and its generic equivalents may increase the risk of birth defects in unborn babies. In a recent press statement, Doctor Russell Katz, the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research said, “Alternative medications that have a lower risk of birth defects should be considered.”
TOPAMAX MAY CAUSE CLEFT LIP AND CLEFT PALATE BIRTH DEFECTS
Cleft lip and cleft palate are birth defects that occur when parts of the lip or palate do not completely fuse together. The severity of these birth defects can vary considerably depending on individual circumstance, but in some cases they are known to cause problems with a child’s ability to eat and talk. Oftentimes surgery is required to close the lip and palate.
If you or your child has been injured as a result of exposure to Topamax®, Burg Simpson’s award-winning dangerous drug attorneys would be happy to provide a free consultation and a review of your records to determine whether you have a viable case against Ortho-McNeil-Janssen Pharmaceuticals, Inc., or any other manufacturer.
Note: At the present time, the FDA has not seen fit to issue a nationwide recall of Topamax® or any of its generic equivalents, and the drug still remains commercially available.
Topamax® is a registered trademark of Ortho-McNeil-Janssen